- Home
- KIDS vs CRGX Comparison
KIDS vs CRGX Comparison
Compare KIDS & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- CRGX
- Stock Information
- Founded
- KIDS 2007
- CRGX 2021
- Country
- KIDS United States
- CRGX United States
- Employees
- KIDS N/A
- CRGX N/A
- Industry
- KIDS Medical/Dental Instruments
- CRGX
- Sector
- KIDS Health Care
- CRGX
- Exchange
- KIDS Nasdaq
- CRGX Nasdaq
- Market Cap
- KIDS 601.5M
- CRGX 628.6M
- IPO Year
- KIDS 2017
- CRGX 2023
- Fundamental
- Price
- KIDS $24.26
- CRGX $3.70
- Analyst Decision
- KIDS Buy
- CRGX Hold
- Analyst Count
- KIDS 6
- CRGX 7
- Target Price
- KIDS $37.67
- CRGX $4.67
- AVG Volume (30 Days)
- KIDS 317.8K
- CRGX 1.9M
- Earning Date
- KIDS 03-05-2025
- CRGX 03-20-2025
- Dividend Yield
- KIDS N/A
- CRGX N/A
- EPS Growth
- KIDS N/A
- CRGX N/A
- EPS
- KIDS N/A
- CRGX N/A
- Revenue
- KIDS $189,673,000.00
- CRGX N/A
- Revenue This Year
- KIDS $39.26
- CRGX N/A
- Revenue Next Year
- KIDS $18.08
- CRGX N/A
- P/E Ratio
- KIDS N/A
- CRGX N/A
- Revenue Growth
- KIDS 33.47
- CRGX N/A
- 52 Week Low
- KIDS $21.02
- CRGX $3.00
- 52 Week High
- KIDS $35.99
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- KIDS 45.67
- CRGX 20.88
- Support Level
- KIDS $23.55
- CRGX $3.00
- Resistance Level
- KIDS $25.45
- CRGX $3.88
- Average True Range (ATR)
- KIDS 1.26
- CRGX 0.92
- MACD
- KIDS -0.28
- CRGX -1.00
- Stochastic Oscillator
- KIDS 20.48
- CRGX 5.99
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.